SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Nasus Pharma Ltd. (NSRX) has a negative trailing P/E of -13.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -7.35%.
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+895.5%).
- Trailing Earnings Yield -7.35% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
- Analyst consensus target $22.00 (+895.5% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 45/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NSRX
Valuation Multiples
P/E (TTM)-13.6
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA-13.0
Per Share Data
EPS (TTM)$-0.17
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings Yield-7.35%
Dividend Yield0.00%
Analyst Target$22.00 (+895.5%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2022 |
-43.7 |
0.00 |
0.00 |
0.00 |
- |
| 2023 |
-71.1 |
1.93 |
0.00 |
0.00 |
- |
| 2024 |
-48.8 |
-1.17 |
0.00 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2022 |
$-0.19 |
$0.00 |
$-1.71M |
- |
| 2023 |
$-0.12 |
$0.00 |
$-1.05M |
- |
| 2024 |
$-0.17 |
$0.00 |
$-1.53M |
- |
